Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DBI-001 and DBI-002 Gel for Interdigital Tinea Pedis
NCT05493488Phase 2Unknown
- Sponsor
- DermBiont, Inc.
- Start
- Sep 2022
- Primary completion
- Dec 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of DBI-001 and DBI-002 probiotic gel in interdigital tinea pedis (TP) (3 arms), sponsored by DermBiont, Inc. Primary endpoint: Change in abundance of T. rubrum based on Quantitative Polymerase Chain Reaction (qPCR) at 14 days. Status: unknown.
02
Drugs
DBI-001DBI-002 probiotic gel
03
Conditions
interdigital tinea pedis (TP)
Beyond the preview
Go deeper on NCT05493488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05493488.